{"entity":{"id":"nct05053880","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in glioma & glioblastoma, run by Accendatech USA Inc., active and no longer recruiting.","summary":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme is a phase 1/2 interventional study registered as NCT05053880 by Accendatech USA Inc., with 48 participants enrolled, started 2021-09-22 and due to reach its primary completion in 2024-10-25. Interventions recorded: ACT001 and ACT001 + Pembrolizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05053880","url":"https://clinicaltrials.gov/study/NCT05053880"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05053880","phase":"1/2","setting":"A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","sponsor":"Accendatech USA Inc.","started":"2021-09-22","startedType":"actual","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05053880/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}